Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria.

Competing Interests: Disclosure FC: consulting/advisory for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline (GSK), Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seattle Genetics, Teva. MMR: research resources (to institution) for clinical trials from Novartis, Pfizer, Ipsen, TerSera, Merck, Ferring, Pierre Fabre, Roche, AstraZeneca, Bristol-Myers Squibb, Bayer; consulting or advisory role (personal) to Bristol-Myers Squibb, Tolmar Pharmaceuticals; honoraria from WebMD. MPG: reports consulting fees (all to institution) from Eagle Pharmaceuticals, Eli Lilly, Biovica, Novartis, Sermonix, Context Pharm, Pfizer, and Biotheranostics. Research funding from the National Cancer Institute, National Institutes of Health, Department of Defense, Mayo Development, Eli Lilly, Pfizer, Alliance Foundation Trials, Sermonix Pharmaceutical, Translational Breast Cancer Research Consortium, and Minnesota Partnership for Biotechnology and Medical Genomics. SH: contracted research (to institution): Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, Zymeworks, Phoenix Molecular Designs, Ltd. Travel: Lilly (2019). LM: research resources (to institution) for clinical trials from AstraZeneca, Eli Lilly and Company, Hoffman-La Roche, Pfizer, Radius Pharmaceuticals; consulting or advisory role (personal) to BioTheranostics. CH: Roche/Genentech (honoraria, consulting/advisory), Pfizer (consulting/advisory), Johns Hopkins Hospital (consulting/advisory), NIH/NCI Cancer Moonshot (consulting/advisory), Eli Lilly (travel, accommodations, expenses). All other authors have declared no conflicts of interest.